Sugi Predict

Sugi Predict / Compounds / SCHEMBL18009669

SCHEMBL18009669

SCHEMBL18009669

Fc1c[nH]c2nc(Cl)ncc12

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA5 O75582 2/20 0.40
▸ TYRO3 Q06418 1/20 0.38
▸ DYRK1B Q9Y463 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MAPT P10636 1/20 0.31
▸ POLB P06746 1/20 0.30
▸ CASP6 P55212 1/20 0.30
▸ JUN P05412 1/20 0.30
▸ NFKB1 P19838 1/20 0.30
▸ NFKB2 Q00653 1/20 0.30
▸ RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22518633 0.80 RPS6KA5 (0.45) RPS6KA5TYRO3DYRK1BKDM4E
SCHEMBL19667381 0.77 PDK2 (0.44) DYRK1B
SCHEMBL1446801 0.77 RPS6KA5 (0.40) RPS6KA5TYRO3DYRK1BALDH1A1KDM4E
SCHEMBL30475606 0.77 TYRO3 (0.42) RPS6KA5TYRO3DYRK1BKDM4E
SCHEMBL12120921 0.77 TYRO3 (0.42) RPS6KA5TYRO3DYRK1BKDM4E
SCHEMBL14842412 0.77 AXL (0.47) RPS6KA5TYRO3DYRK1BKDM4EKMT2A
SCHEMBL23725349 0.73 KMT2A (0.47) RPS6KA5TYRO3DYRK1BALDH1A1KDM4E
SCHEMBL30899087 0.73 LRRK2 (0.47) RPS6KA5TYRO3DYRK1B
SCHEMBL28274262 0.73 LRRK2 (0.47) RPS6KA5TYRO3DYRK1B
SCHEMBL30989367 0.72 RPS6KA5 (0.34) RPS6KA5TYRO3DYRK1BKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS INCYTE CORP (US) 2026-03-12 — — US disclosed
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 — — US disclosed
US-12173026-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-12-24 — — US disclosed
EP-4469448-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2024-12-04 — — EP disclosed
CN-112805006-B PRMT5 inhibitors 默沙东有限责任公司 2024-09-24 — — CN disclosed
CN-118591537-A PARP7 inhibitors 吉利德科学公司 2024-09-03 — — CN disclosed
CN-117417355-A Fused heterocyclic compound, preparation method and application thereof 上海翊石医药科技有限公司 2024-01-19 — — CN disclosed
CN-117412971-A Pyrrolopyrimidine derivatives containing pyrazine structures 微境生物医药科技(上海)有限公司 2024-01-16 — — CN disclosed
US-20230365529-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
WO-2023217201-A2 NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF 杭州德睿智药科技有限公司 2023-11-16 — — WO disclosed
EP-3262057-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Inc (US) 2018-01-03 — — EP disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 — — US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 — — US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 — — US disclosed
WO-2016135582-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-09-01 — — WO disclosed
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-08-25 — — US disclosed
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-08-25 — — US disclosed
CN-101827848-B 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer GLAXOSMITHKLINE LLC 2012-11-07 — — CN disclosed
CN-102307875-A Pyrrolopyrimidinyl axl kinase inhibitors SUPERGEN INC 2012-01-04 — — CN disclosed
CN-101827848-A 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer SMITHKLINE BEECHAM CORP 2010-09-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS TYMP, NME1, PNP RPS6KA5 445/4885TYRO3 4350/4885DYRK1B 4771/4885
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS CDK4, CDK2, CCNC RPS6KA5 198/4885TYRO3 2798/4885DYRK1B 1490/4885
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP RPS6KA5 450/4885TYRO3 4649/4885DYRK1B 4755/4885
US-12173026-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 RPS6KA5 502/4885TYRO3 2603/4885DYRK1B 3566/4885
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 RPS6KA5 515/4885TYRO3 3140/4885DYRK1B 466/4885
US-20230365529-A1 PARP7 INHIBITORS PARP1, PARP11, PARP2 RPS6KA5 515/4885TYRO3 3140/4885DYRK1B 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.